Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin

Rheumatology International

Volumn 19, Issue 4, 2000, Pages 129-136

  Cooper, T ^a   Savige, J ^a   Nassis, L ^a   Paspaliaris, B ^a   Neeson, P ^a   Neil, J ^c   Knight, K R ^b   Daskalakis, M ^d   Doery, J C G ^d  

^a AUSTIN HEALTH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c QUEENSLAND HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

ANCA; Azurocidin; BPI; Cystic fibrosis; Ulcerative colitis

Indexed keywords

ALPHA 1 ANTITRYPSIN; AUTOANTIBODY; AZUROCIDIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CELL NUCLEUS DNA; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY AFFINITY; ARTICLE; CROHN DISEASE; CYSTIC FIBROSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIXED CONNECTIVE TISSUE DISEASE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; WEGENER GRANULOMATOSIS;

ALPHA 1-ANTITRYPSIN; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIMICROBIAL CATIONIC PEPTIDES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD PROTEINS; CARRIER PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOGLOBULINS; MEMBRANE PROTEINS; PHENOTYPE;

EID: 0034054541     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960050116     Document Type: Article

References (50)

1. 1. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem GK, The TH (1985) Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and marker for disease activity in Wegener's granulomatosis. Lancet I: 425-429
2. 2. Savige JA, Gillis D, Benson EB, Davies DJ, Esnault V, Falk R, Hagen EC, Jayne D, Jennette JC, Paspaliaris B, Pollock W, Pusey CD, Savage COS, Silvestrini R, van der Woude FJ, Wieslander J, Wiik A (1999) International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111: 507-513
3. 3. Lock RJ (1994) Detection of autoantibodies to neutrophil cytoplasmic antigens. J Clin Pathol 47: 4-8
4. 4. Faber V, Elling P (1967) Leucocyte-specific antinuclear factors in patients with Felty's syndrome, rheumatoid arthritis, systemic lupus erythematosus and other diseases. Acta Med Scand 179: 257
5. 5. Wiik A (1980) Granulocyte-specific antinuclear antibodies. Allergy 35: 263-189
6. 6. Savage COS, Winearls CG, Jones S, Marshall PD, Lockwood CM (1987) Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet I: 1389-1393
7. 7. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, Hack CE, van den Ende ME, Kallenberg CG, von dem Borne AE (1989) Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 84: 1577-1587
8. 8. Niles JL, McCluskey RT, Ahmad MF, Arnaout MA (1989) Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 74: 1888-1893
9. 9. Falk RJ, Jennette JC (1988) Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and crescentic glomerulonephritis. N Engl J Med 318: 1651-1657
10. 10. Nassberger L, Jonsson H, Sjoholm AG, Sturfelt G, Heubner A (1989) Circulating antielastase in systemic erythematosus. Lancet I: 509
11. 11. Flesch BK, Lampe M, Rautman A, Gross WL (1991) Anti-elastase, cathepsin G and lactoferrin antibodies in sera with C-ANCA or with atypical fluorescence staining pattern (abstract). Am J Kidney Dis 18: 201A
12. 12. Schmitt WH, Csernok E, Flesch BK, Hauschild S, Gross WL (1993) Autoantibodies directed against lysozyme: a new target antigen of antineutrophil cytoplasmic antibodies (ANCA). Adv Exp Med Biol 336: 267-272
13. 13. Wiik A, Kjeldsen L, Borregard N, Ullman S, Jacobsen S, Halberg P (1995) The diversity of perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) antigens. Clin Exp Immunol 101: 15-17
14. 14. Zhao MG, Jones SJ, Lockwood CM (1995) Bactericidal/ permeability-increasing protein (BPI) is an important antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 99: 49-56
15. 15. Zhao MH, Lockwood CM (1996) Azurocidin is a novel antigen for antineutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 103: 397-402
16. 16. Gray PW, Flaggs G, Leong SR, Gumina RJ, Weiss J, Ooi CE, Elsbach P (1989) Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem 264: 9505-9509
17. 17. Weiss J, Victor M, Stendhal O, Elsbach P (1982) Killing of gram-negative bacteria by polymorphonuclear leucocytes. Role of an O2-independent bactericidal system. J Clin Invest 69: 959-970
18. 18. Ooi CE, Weiss J, Doerfler ME, Elsbach P (1991) Endotoxin-neutralising properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55-60 kD bactericidal/ permeability-increasing protein of human neutrophils. J Exp Med 174: 649-655
19. 19. Stoffel MP, Csernok E, Herzberg C, Johnston T, Carroll SF, Gross WL (1996) Antineutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability-increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 104: 54-59
20. 20. Walmsley RS, Zhao MH, Hamilton MI, Brownlee A, Chapman P, Pounder RE, Wakefield AJ, Lockwood CM (1997) Antineutrophil cytoplasmic autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut 40: 105-109
21. 21. Zhao M-H, Jayne DRW, Ardiles L, Culley F, Hodson ME, Lockwood CM (1996) Autoantibodies against bactericidal/ permeability-increasing protein (BPI) in patients with cystic fibrosis. QJM 89: 259-265
22. 22. Yang JJ, Tuttle R, Falk RJ, Jennette JC (1996) Frequency of antibactericidal/permeability-increasing protein (BPI) and antiazurocidin in patients with renal disease. Clin Exp Immunol 105: 125-131
23. 23. Campanelli D, Detmers PA, Nathan CF, Gabay JE (1990) Azurocidin and a homologous serine protease from neutrophils. Differential antimicrobial and proteolytic properties. J Clin Invest 85: 904-915
24. 24. Miyasaki KT, Bodeau AL (1992) Human neutrophil azurocidin synergises with leucocyte elastase and cathepsin G in the killing of Capnocytophaga sputigena. Infect Immun 60: 4973-4875
25. 25. Esnault VLM, Testa A, Audrain M, Roge C, Hamidou M, Barrier JH, Sesboue R, Martin J-P, Lesavre P (1993) α1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 43: 1329-1332
26. 26. Elzouki ANY, Segelmark M, Wieslander J, Eriksson S (1994) Strong link between the α1-antitrypsin PiZ allele and Wegener's granulomatosis. J Intern Med 236: 543-548
27. 27. Savige JA, Chang L, Cook L, Burdon J, Daskalakis M, Doery J (1995) α1-antitrypsin deficiency and antiproteinase 3 antibodies in ANCA-associated systemic vasculitis. Clin Exp Immunol 100: 194-197
28. 28. Segelmark M, Elzouki A-N, Wieslander J, Eriksson S (1995) The PiZ gene of α1 antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. Kidney Int 48: 844-850
29. 29. O'Donoghue DJ, Guckian M, Blundell G, Winney RJ (1993) al antiproteinase and pulmonary haemorrhage in systemic vasculitis. Adv Exp Med Biol 336: 331-335
30. 30. van der Wiel BA, Dolman KM, Goldschmeding R, von dem Borne AEGKr, Hack CE (1991) α1-antitrypsin is the major inhibitor of the 29 kD C-ANCA antigen (abstract). Am J Kidney Dis 18: 206A
31. 31. Dolman KM, Stegeman CA, van de Wiel BA, Hack CE, von dem Borne AEGKr, Kallenberg CGM, Goldschmeding R (1993) Relevance of classic antineutrophil cytoplasmic autoantibody (C-ANCA)-mediated inhibition of proteinase 3-α1 antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 93: 405-410
32. 32. Wiik A (1988) Delineation of a standard procedure for indirect immunofluorescence of ANCA. APMIS 97: 12
33. 33. Jeppsson J-O, Franzen B (1982) Typing of genetic variants of α1-antitrypsin by electrofocusing. Clin Chem 28: 219-225
34. 34. Segelmark M, Baslund B, Wieslander J (1994) Some patients with antimyeloperoxidase antibodies have a C-ANCA pattern. Clin Exp Immunol 96: 458-465
35. 35. Savige JA, Paspaliaris B, Davies DJ, Sturgess A, Neil J, Pollock W, Dunster K, Hendle M (1998) Immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other auto- and alloantibodies. J Clin Pathol 51: 568-575
36. 36. Stroncek DF, Egging MS, Eiber GA, Caly ME (1993) Neutrophil alloantibodies react with cytoplasmic antigens as possible cause of false-positive indirect immunofluorescence assays for antibodies to neutrophil cytoplasmic antigens. Am J Kidney Dis 21: 368-373
37. 37. Sediva A, Bartunkova J, Kolarova I, Vavrova V (1996) ANCA with specificity for bactericidal/permeability-increasing protein in children with cystic fibrosis. Sarcoidosis, vasculitis and diffuse lung diseases (abstract). 13: 275A
38. 38. Short AK, Lockwood CM, Bollen A, Moguilevsky N (1995) Neutrophil and recombinant myeloperoxidase as antigens in ANCA positive systemic vasculitis. Clin Exp Immunol 102: 106-111
39. 39. Herzberg C, Csernok E, Stoffel M, Carroll SF, Szymkowiak C, Gross WL (1995) Disease associations of ANCA with specificity for bactericidal/permeability-increasing protein (BPI) (abstract). Clin Exp Immunol 101 [Suppl 1]: 41A
40. 40. Cox DW, Huber O (1976) Rheumatoid arthritis and α1 antitrypsin. Lancet 1: 1216
41. 41. Buisseret PD, Pembrey ME, Lessof MH (1977) α1 antitrypsin phenotypes in rheumatoid arthritis and ankylosing spondylitis. Lancet 2: 1358
42. 42. Doring G, Krogh-Johansen H, Wiedeinger S, Hoiby N (1994) Allotypes of α1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508. Pediatr Pulmonol 18: 3-7
43. 43. Jayne DRW, Jones SJ, Severn A, Shaunak S, Murphy J, Lockwood CM (1989) Severe pulmonary haemorrhage and systemic vasculitis in association with circulating antineutrophil cytoplasm antibodies of IgM class only. Clin Nephrol 32: 101-106
44. 44. Rubin RL, Tang FL, Chan EKL, Pollard KM, Tsay G, Tan EM (1986) IgG subclasses of autoantibodies in systemic lupus erythematosus, Sjogren's syndrome, and drug-induced autoimmunity. J Immunol 137: 2528-2534
45. 45. Jayne DRW, Weetman AP, Lockwood CM (1991) IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol 84: 476-481
46. 46. Brouwer E, Cohen Tervaert JW, Horst G, Huitema MG, van der Giessen M, Limburg PC, Kallenberg CGM (1991) Predominance of IgG1 and IgG4 subclasses of antineutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 83: 379-386
47. 47. Esnault VLM, Ronda N, Jayne DRW, Lockwood CM (1993) Association of ANCA isotype and affinity with disease expression. J Autoimmun 6: 197-205
48. 48. Bini P, Gabay JE, Yeitel A, Melchior M, Zhou J-L, Elkon KB (1992) Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognise conformational epitope(s) on proteinase 3. J Immunol 149: 1409-1415
49. 49. Falk RJ, Becker M, Terrell R, Jennette JC (1992) Antimyeloperoxidase autoantibodies react with native but not with denatured myeloperoxidase. Clin Exp Immunol 89: 274-278
50. 50. Chang L, Binos S, Savige J (1995) Epitope mapping of antiproteinase 3 and antimyeloperoxidase. Clin Exp Immunol 102: 112-119